Here are five notes:
1. The phase 3 UNITI-2 study, sponsored by Janssen Research & Development, focused on examining the efficacy and safety of STELARA, is a monoclonal antibody that targets interleukin-12 and IL-23 cytokines.
2. Patients participating in the study received a single intravenous infusion of placebo, STELARA 130 mg or STELARA ~6 mg/kg.
3. At week six, 52 percent of patients receiving STELARA 130 mg and 56 percent of patients receiving STELARA ~6 mg/kg achieved clinical response.
4. At week eight, 47 percent and 58 percent of patients receiving STELARA 130 mg and STELARA ~6 mg/kg respectively achieved clinical response, compared with 32 percent of patients receiving placebo.
5. STELARA also resulted in statistically significant improvements in the Inflammatory Bowel Disease Questionnaire, a health-related quality of life measure for IBD patients.
More articles on GI/endoscopy:
3 GI physicians in the news – Oct. 16, 2015
ACG elects Dr. Kenneth DeVault president: 5 things to know
5 most-read GI/endoscopy stories – Week of Oct 12 to Oct. 16
